Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WELCOME: Certolizumab pegol in Crohn's Disease after Infliximab failure
NCT00308581Phase 3Completed
- Sponsor
- UCB
- Start
- Apr 2006
- Primary completion
- Apr 2008
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 14
01
Overview
A Phase 3 trial of certolizumab pegol in Crohn's disease, sponsored by UCB. Started Apr 2006; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00308581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00308581.